(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today is announcing new staff additions and a promotion within its State Affairs department. Sam Hallemeier joins PCMA as Director, State Affairs. Sam brings broad industry experience, having worked in both
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement in response to a letter issued by the Centers for Medicare and Medicaid Services (CMS): “The Pharmaceutical Care Management Association, PCMA, representing America’s pharmacy benefit companies, believes it is
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) will hold its annual “PBM Policy Forum” tomorrow, April 19, at the Newseum in Washington, D.C. This year’s event features subject matter experts explaining key issues in the drug supply chain
Insulin list prices have escalated dramatically during the past 5-10 years. This is due to only three manufacturers controlling the market, the lack of alternative insulins, and manufacturer abuse of patent extensions. PBMs drive competition using drug formularies and rebates.
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part II:” “We commend the Senate Finance Committee for
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the recent ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready. In a unanimous decision, the court sustained PCMA’s challenge to four provisions of
Health Equity Working together for a more equitable health care system. Pharmacy benefit companies, in collaboration with plan sponsors, clinicians, and government programs, have a long history of working to advance health equity; however, the severity of the health disparities
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Medicare Part D final rule released yesterday by the Department of Health and Human Services: “Two years ago drugmakers launched a
After biosimilars launch, reference biologics’ list price increases stop and net costs fall. Currently, 7 reference biologics have at least 1 biosimilar competitor on the market, creating direct competition for those drugs.
©2024 PCMA. All Rights Reserved.
